About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 68681 record(s)
Req # A-2023-000212
Adverse Drug Reactions (ADRs). Report numbers: E2B_06042674, E2B_06191755, 001027968, E2B_06179338, 001028307, 001039442, 001029988, 001030424, E2B_06152243.Organization: Health Canada
March 2024
Req # A-2023-000379
Adverse Drug Reactions (ADRs). Report numbers: E2B_06260941, E2B_06232105.Organization: Health Canada
March 2024
Req # A-2023-000452
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_06305106, E2B_06329467, E2B_06320786. ADRs for MESALAZINE. Report numbers: E2B_06319865, E2B_06304517, 001036580, 001037459.Organization: Health Canada
March 2024
Req # A-2023-000722
Adverse Drug Reactions (ADRs). Report numbers: E2B_06176930, 001028202, E2B_05043142, E2B_06132086, E2B_06151402, E2B_04700794, E2B_02294819, E2B_06162162, E2B_04948393 E2B_05337204.Organization: Health Canada
March 2024
Req # A-2023-000835
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104454-497.Organization: Health Canada
March 2024
Req # A-2023-000867
Adverse Drug Reactions (ADRs). Report numbers: E2B_04483418, 000975144, 000977212, 001010854, E2B_04779384, E2B_04800606, E2B_04877938, 000993771, 000996067 000993460.Organization: Health Canada
March 2024
Req # A-2023-000873
Adverse Drug Reactions (ADRs). Report numbers: 001020619, E2B_06058464, E2B_05992299 , E2B_05973308, E2B_05992323, E2B_05992299, E2B_05972707, E2B_05998320, E2B_05974945, 001019223.Organization: Health Canada
March 2024
Req # A-2023-000908
Adverse Drug Reaction (ADR) for Tecta. Report number: E2B_06483597. ADRs for Mesalazine. Report numbers: E2B_06501204, E2B_06486442, E2B_06479972, E2B_06510119, E2B_06482978, E2B_06479977, E2B_06522595. ADRs for VYVANSE. Report numbers: 001049057,…Organization: Health Canada
March 2024
Req # A-2023-000914
Adverse Drug Reactions (ADRs). Report numbers: 001047973, 001043279.Organization: Health Canada
March 2024
Req # A-2023-000915
Adverse Drug Reactions (ADRs). Report numbers: E2B_06142348, E2B_06142824.Organization: Health Canada
March 2024